Abstract 3917: Regulatory role of ROBO-1, a novel tumor suppressor on Androgen receptor and Wnt signaling during castration-resistant prostate cancer development: A novel molecular target for gene therapy

2012 ◽  
Author(s):  
Mohammad Saleem ◽  
Hifzur R. Siddique ◽  
Ramesh Ganju ◽  
Shrawan K. Mishra ◽  
Hiroyuki Aburatani
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
Androgen Receptor ◽  
Wnt Signaling ◽  
Molecular Target ◽  
Cancer Development ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Prostate Cancer Development

scholarly journals Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer

2019 ◽  
Vol 20 (9) ◽  
pp. 2066 ◽  
Author(s):  
Namrata Khurana ◽  
Suresh C. Sikka
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Signaling Pathways ◽  
Critical Role ◽  
Castration Resistant Prostate Cancer ◽  
Form Complex ◽  
Androgen Receptor Signaling ◽  
Castration Resistant ◽  
Signaling Axis

Androgen receptor (AR) signaling plays a key role not only in the initiation of prostate cancer (PCa) but also in its transition to aggressive and invasive castration-resistant prostate cancer (CRPC). However, the crosstalk of AR with other signaling pathways contributes significantly to the emergence and growth of CRPC. Wnt/β-catenin signaling facilitates ductal morphogenesis in fetal prostate and its anomalous expression has been linked with PCa. β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa. The transcription factor SOX9 has been shown to be the driving force of aggressive and invasive PCa cells and regulate AR expression in PCa cells. Furthermore, SOX9 has also been shown to propel PCa by the reactivation of Wnt/β-catenin signaling. In this review, we discuss the critical role of SOX9/AR/Wnt/β-catenin signaling axis in the development and progression of CRPC. The phytochemicals like sulforaphane and curcumin that can concurrently target SOX9, AR and Wnt/β-catenin signaling pathways in PCa may thus be beneficial in the chemoprevention of PCa.

Abstract C16: Targeting AR in castration-resistant prostate cancer: Development of ARN-509 and second-generation antiandrogen resistance models

2012 ◽  
Vol 72 (4 Supplement) ◽  
pp. C16-C16
Author(s):  
James D. Joseph ◽  
Anna Aparicio ◽  
Josh Kaufman ◽  
Jackie Julien ◽  
Celine Bonnefous ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Second Generation ◽  
Cancer Development ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Prostate Cancer Development

scholarly journals Second-generation androgen receptor inhibitors in therapy of non-metastatic castration resistant prostate cancer: role of safety profile and effect on quality of life

2021 ◽  
Vol 67 (2) ◽  
pp. 217-226
Author(s):  
Elena Ushkalova ◽  
Sergey Zyryanov ◽  
Irina Gopienko
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Receptor ◽  
Safety Profile ◽  
Second Generation ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Clinically Significant

The article discusses the role of second-generation androgen receptor inhibitors (ARi) in therapy of non-metastatic castration resistant prostate cancer (nmCRPC). The phase 3 trials PROSPER (enzalutamide), SPARTAN (apalutamide) and ARAMIS (darolutamide) showed that these medicines if used in combination with androgen deprivation therapy (ADT) make possible to significantly improve, as compared with placebo, metastasis-free survival and overall survival of patients with nmCRPC. An important role in choosing a certain medicine of the group is played by its safety profile, including its drug-drug interaction potential and effect on patient’s quality of life. In this respect, darolutamide has a number of advantages over apalutamide or enzlutamide. The frequency of CNS (cognitive, psychiatric, convulsive) and other adverse drug reactions that significantly worsen the patients’ quality of life (falls, fractures, hypertension, etc.) in therapy with darolutamide does not differ from that with placebo. Moreover, this medicine retains its antagonistic effects to all clinically significant androgen receptor mutations that develop resistance to enzalutamide and apalutamide.

Sign in / Sign up

Export Citation Format

Share Document